Sun Pharmaceutical Industries Limited has received regulatory approval from the Brazilian Health Regulatory Agency, ANVISA, to manufacture and market semaglutide injection in Brazil. The approval permits the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, marking a significant expansion of its diabetes portfolio in Latin America. Management intends to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil, capitalizing on a semaglutide injectable market estimated at approximately USD 413 million (IQVIA, MAT June 2026).

The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on July 29, 2026. The filing confirms that Sun Pharma holds the necessary manufacturing and marketing rights for the drug in the region. The product will be available as a pre-filled, multi-dose injectable pen, offering flexible once-weekly dosing options for patients.

Product Specifications

The approved semaglutide formulation is designed for ease of use and adherence, featuring two distinct strengths:

Management Commentary

Aalok Shanghvi, Chief Operating Officer at Sun Pharma, stated that the approval expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. He noted that the milestone reflects the strength of the company's development and manufacturing capabilities and its commitment to delivering high-quality medicines across global markets.

Digvijay Singh, Regional Head for Brazil & LATAM, emphasized that this approval marks an important step in strengthening the diabetes portfolio in Brazil. He expressed anticipation for working closely with the partner to make this treatment option available to patients and support better diabetes care across the country.

Market Context

The entry into the Brazilian semaglutide market positions Sun Pharma to compete in a sector valued at approximately USD 413 million, according to IQVIA data for the month ending June 2026. By securing both manufacturing and marketing approvals, Sun Pharma bypasses the need for third-party sourcing, potentially improving margin structures compared to pure distribution deals. The partnership with Hypera Pharma leverages local expertise to accelerate market penetration, while the dual-strength offering (2 mg and 4 mg) allows for dose titration, a critical factor in patient adherence for chronic conditions like type 2 diabetes. This move aligns with Sun Pharma's broader strategy to expand its presence in Global Emerging Markets, where it already maintains a significant footprint alongside its US generics business.

sun pharmaceutical Industries Ltd. witnessed a notable block trade on the National Stock Exchange (NSE), amounting to ₹198.88 crores. The transaction was executed at a price of ₹1982.60 per share, involving approximately 1,003,116 shares.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades are large-volume transactions typically executed between institutional participants outside the regular order book, and are often indicative of significant portfolio activity by institutional investors. The trade in Sun Pharmaceutical Industries Ltd. represents a sizeable movement in the counter, reflecting notable interest at the ₹1982.60 price level.